Evaluating 3K3A-APC in Patients With ALS: Kent Pryor, PhD
The CEO of ZZ Biotech outlined the design of the phase 2 trial of 3KA-APC, which will enroll 16 patients with amyotrophic lateral sclerosis. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
“There are basically 2 broad categories of approaching ALS clinical research right now. One is going after genetic forms of the disease—looking at a particular slice of patients and going after it that way. But what 3K3A-APC does, it addresses the underlying pathologies of the disease, pretty much regardless of the genetic aspects of the disease.”
A phase 2 clinical trial (NCT05039268) of an investigational treatment from ZZ Biotech,
NeurologyLive® recently sat down with the CEO of ZZ Biotech,
Pryor spoke on the unique aspects of the phase 2 trial, noting that investigators are still working to identify the optimal dosing regimen in patients with ALS. The regimen was also used in the phase 1 study and the phase 2 RHAPSODY trial (NCT02222714) in stroke, Pryor said, with the current trial helping to give investigators a better idea of the treatment’s ability to move different biomarkers and impact the ALS disease state.
REFERENCE
ZZ Biotech announces first patients doses in phase 2 clinical trial of 3K3A-APC for treatment of amyotrophic lateral sclerosis. News release. ZZ Biotech. December 2, 2021. Accessed December 10, 2021. https://www.biospace.com/article/releases/zz-biotech-announces-first-patients-dosed-in-phase-2-clinical-trial-of-3k3a-apc-for-treatment-of-amyotrophic-lateral-sclerosis-als-/
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Perispinal Etanercept Shows No Efficacy in Treating Chronic Stroke
September 16th 2025